enzastaurin

A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2018
010203020042018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND glioblastomas are highly vascularized tumors and various antiangiogenic drugs have been investigated in clinical… (More)
  • table 1
  • figure 2
  • table 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
GNAQ mutations at codon 209 have been recently identified in approximately 50% of uveal melanomas (UM) and are reported to be… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2010
2010
Enzastaurin, a potent inhibitor of protein kinase C-beta, inhibits angiogenesis and has direct cytotoxic activity against glioma… (More)
Is this relevant?
2010
2010
We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Protein kinase C beta (PKCbeta) was identified by gene-expression profiling, preclinical evaluation, and independent… (More)
Is this relevant?
2007
2007
Waldenström macroglobulinemia (WM) is an incurable lymphoplasmacytic lymphoma with limited options of therapy. Protein kinase… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
OBJECTIVE Radiotherapy is an essential treatment modality for malignant gliomas, but it exerts adverse effects via promotion of… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE This phase I study was conducted to determine the recommended dose of enzastaurin, an oral protein kinase C beta (PKCbeta… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Activation of protein kinase Cbeta (PKCbeta) has been repeatedly implicated in tumor-induced angiogenesis. The PKCbeta-selective… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?